Market Newsdesk

SEOUL, South Korea, Dec. 10, 2020 /PRNewswire/ — Hyosung Chairman Cho Hyun-joon has solidified its world’s No.1 position in the spandex market by increasing the production capacity of the spandex plant in Brazil.

Hyosung TNC (KRX:298020) announced on the 2nd that it will expand the production scale of its spandex plant located in Santa Catarina in the southern part of Brazil by 10,000 tons by December next year through an investment of KRW 40 billion (approx. USD 36 million). Once the expansion is completed, the production capacity of the plant in Santa Catarina will increase to 22,000 tons totally, which is around double the current production capacity.

This expansion was decided in line with a rapid rise in the demand for spandex, a synthetic fiber known for its exceptional stretch, as the sale of comfortable clothing, such as home wear and athleisure wear, increases in the Central and South American clothing market due to the spread of COVID-19.

In the Brazilian market, the import tariff rate for spandex is as high as 18%, which is more than double the rate applied in other regions. Therefore, a local production base is essential for maintaining price competitiveness. In addition, Brazil borders ten of 12 South American countries and abuts on the sea, which are advantageous geographical features for export to nearby regions.

With the plant expansion, Hyosung TNC expects to not only meet the increasing demand in the American region but also preemptively respond to the post-COVID-19 era by solidifying its leadership from the competitors.

The demand for spandex in global apparel market continues to grow due to consumer popularity of comfort and athleisure wear. According global research and consulting firm RESEARCH AND MARKETS 2020 report, spandex demand has been growing by 6 to 7% which is more than double the growth rate of general apparel fibers, which grow 2 to 3% annually.

Having established a production base in Brazil back in 2011, Hyosung TNC has strengthened its market share in the American continent. Currently, the company’s market share in Brazil is the largest at 65%.

“The unprecedented risk caused by COVID-19 has aggravated uncertainty and accelerated the speed of change,” said Hyosung Chairman Cho Hyun-joon. He emphasized, “In times of change, we must turn crisis into opportunity by continuously investing for our future.”

Hyosung TNC established a production base in India for the emerging markets in Asia in addition to a production base in Vietnam to target the entire Asian market. Through the efforts to establish production bases by continent, Hyosung TNC is keeping its unchallenged position as a global leader.

http://www.hyosungtnc.com/en/pr/news_center_v.do?newsCenterSeq=234&openDtm=20180214&page=12

http://www.koreatimes.co.kr/www/tech/2020/11/129_298616.html

About Hyosung

Hyosung is a comprehensive fibre manufacturer that produces world-class products, providing innovation and solutions to the textile industry. Hyosung’s creora® elastane is the world’s largest spandex brand, supplying the broadest range of stretch fibre offerings supported by exceptional technology and quality. Mipan® nylon and specialty polyester provide functional and sustainable fibre solutions that are essential to today’s dynamic textile market. Visit our website at www.hyosungtnc.com and http://www.creora.com for all the latest trend, event and product updates.

Contacts

Hyosung Corporation
Nari Kim
+82-2-707-7067


[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/cho-hyun-joon-hyosung-chairman-undertakes-brazil-spandex-plant-extension-301190116.html

SOURCE Hyosung TNC

SEOUL, South Korea, Dec. 10, 2020 /PRNewswire/ — RSUPPORT Co., Ltd. (www.rsupport.com), a global remote solution company, announced today that it will provide its web-based video conferencing service, RemoteMeeting, for one month free of charge for the year-end and New Year holidays.

RSUPPORT provides the RemoteMeeting service for free from December 10th to January 10th to promote non-contact meetings with family and friends. Anyone can use it for free without sign up, and there is no need to rush and fully convey your nostalgia online since there is no time limit during the event period.

RemoteMeeting allows easy video conferencing through a web browser without installing a separate program. Just click the ‘Start meeting’ button on the RemoteMeeting website (www.remotemeeting.com) and enter a nickname to instantly create a virtual space (meeting room) to meet up. Invite up to 30 family members or friends asking them to simply enter the access code (6 digits random number) or send them email with the connection link as well as by messenger.

It provides an intuitive user environment (UX/UI) that can be easily understood by non-technical users, so that you do not waste time explaining how to use the service. It supports Korean, English, and Japanese to help people get in touch with anyone overseas.

During the event period, businesses also can use RemoteMeeting for free. Most companies used to have frequent meetings before Christmas season, this year, however, it seems unable to have a face-to-face meeting these days due to the COVID-19. In this regard, RSUPPORT has decided to support its RemoteMeeting for free to businesses, so that they are able to continue their business.

RSUPPORT provided its own non-contact solutions for free to support small and medium-sized businesses’ transition to work from home and online classes to schools in response to the spread of COVID-19.

Hyung Su Seo, CEO of RSUPPORT, said, “It is a sort of our privilege to help and support people and businesses with our technology and services during this severe situation, which the number of COVID-19 confirmed cases is rapidly increasing around the world.” He also added “RSUPPORT continues to participate and support the social distancing campaign.”

About RSUPPORT Co., Ltd

Founded in 2001, RSUPPORT Co., Ltd has been one of the pioneers and led the global remote solution industry. RSUPPORT develops and delivers rapid and reliable remote services for consumers, small and medium businesses, and enterprises worldwide.

Based on its advanced remote technologies and accumulated know-how, RSUPPORT provides a comprehensive lineup of remote and non-contact solutions: RemoteMeeting for video conferencing, RemoteView for remote access and control, RemoteCall for remote troubleshooting and support, and RemoteSeminar for the online seminar. 

RSUPPORT delivers its outstanding remote services for more than 10,000 customers worldwide in various industries, including PC and mobile device manufacturers, telecommunications companies, financial companies, etc. That is how RSUPPORT has firmly established its market position and manages sales partners in many countries worldwide.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/rsupport-offers-free-remotemeeting-for-christmas-and-new-years-non-face-to-face-meetings-301188907.html

SOURCE RSUPPORT

CARLSBAD, Calif., Dec. 10, 2020 /PRNewswire/ — Viasat Inc. (NASDAQ: VSAT), a global communications company, announced today its Ka-band ‘no speed limit’ business aviation in-flight connectivity (IFC) service is now available on the super mid-size Gulfstream G280™ airframe.

Viasat removed internet speed limits delivered to G280 aircraft, which will enable passengers and crew an opportunity to maximize their ‘home-like connectivity’ in-flight experiences—with the fastest available business aviation IFC download speeds in the super mid-size business jet segment. The new Ka-band service plans enable concurrent use of business-critical productivity and entertainment apps from video-conferencing, accessing cloud content and email to enjoying high-definition streaming services, live TV and more.

Claudio D’Amico, business area director, Business Aviation, Viasat commented, “In working with Gulfstream to equip their G280 aircraft with our certified equipment, we can enable their customers to have a premium IFC experience. In fact, Gulfstream customers flying with our new ‘no speed limit’ service plans typically experience speeds greater than 40 Mbps, which gives them the freedom to enjoy the internet the way they want to from take-off to landing.”

How Viasat IFC works on the G280
Any Gulfstream G280 business jet equipped with Viasat’s Ka-band Global Aero Terminal 5510 will receive a premium cabin internet experience over the most heavily traveled flight routes. Today, this terminal can communicate with Viasat’s ViaSat-1, ViaSat-2 and KA-SAT satellite platforms, providing internet connectivity from California to the Mediterranean. The terminal will be forward-compatible with Viasat’s next-generation global satellite constellation, ViaSat-3, which will give G280 customers global connectivity, once the satellite system is fully launched and operational.

Service availability
The Viasat business aviation IFC system has received a Supplemental Type Certificate (STC) from the FAA for installation and use on the G280. With this certification, Gulfstream can offer Viasat’s equipment as a customer option on the G280, enabling passengers, crew and pilots to have access to high-speed, high-quality IFC service.

For more information about Viasat’s business aviation solutions, please visit: www.viasat.com/business-aviation or reach out to: [email protected].

About Viasat
Viasat is a global communications company that believes everyone and everything in the world can be connected. For more than 30 years, Viasat has helped shape how consumers, businesses, governments and militaries around the world communicate. Today, the Company is developing the ultimate global communications network to power high-quality, secure, affordable, fast connections to impact people’s lives anywhere they are—on the ground, in the air or at sea. To learn more about Viasat, visit: www.viasat.com, go to Viasat’s Corporate Blog, or follow the Company on social media at: Facebook, Instagram, LinkedIn, Twitter or YouTube.

Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934. Forward-looking statements include statements about the experience passengers and crew can expect on Gulfstream G280 aircraft; and the forward-compatibility of Viasat’s Global Aero Terminal 5510 with its ViaSat-3 satellite system. Readers are cautioned that actual results could differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ include: our ability to successfully implement our business plan for our broadband services on our anticipated timeline or at all; risks associated with the construction, launch and operation of satellites, including the effect of any anomaly, operational failure or degradation in satellite performance; contractual problems, product defects, manufacturing issues or delays, changes in relationships with, or the financial condition of, key suppliers, and technologies that do not perform according to expectations. In addition, please refer to the risk factors contained in Viasat’s SEC filings available at www.sec.gov, including Viasat’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Viasat undertakes no obligation to update or revise any forward-looking statements for any reason.

Copyright © 2020 Viasat, Inc. All rights reserved. Viasat, the Viasat logo and the Viasat signal are registered trademarks of Viasat, Inc. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

Editor’s note: “No speed limits” means that there is no cap set on the speed delivered to a terminal. Speeds may still be limited by terminal equipment capabilities, network and environmental conditions, and other factors.

 

View original content:http://www.prnewswire.com/news-releases/viasats-no-speed-limit-ka-band-in-flight-connectivity-service-plans-now-available-on-gulfstream-g280-aircraft-301190161.html

SOURCE Viasat, Inc.

PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), an emerging biotech company with next-generation technology in vaccines – both preventive and therapeutic, today announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. The Phase 2 clinical trial being conducted in China is independent of the INNOVATE Phase 2/3 clinical trial of INO-4800 being advanced in the U.S. and will enroll approximately 640 participants who are 18 years or older. Advaccine is conducting and funding the Phase 2 trial in China, which is expected to fully enroll by the end of this month.

Dr. J. Joseph Kim, President and CEO of INOVIO, said, “We have accelerated the development of INO-4800, our DNA vaccine candidate for COVID-19, in China by working together and leveraging Advaccine’s expertise with Chinese regulatory authorities and clinical trial management. We are grateful for our collaboration with Advaccine and its founder Dr. Bin Wang, China’s premier DNA vaccine expert and Emeritus Professor from Fudan University. Our teams are pleased with the progress to date and our ability to accelerate our clinical work in China with the goal of developing and delivering a safe, tolerable, effective and lasting vaccine for COVID-19.

Dr. Bin Wang, Founder of Advaccine, said, “We are truly grateful for Advaccine to co-develop INO-4800 against COVID-19 with INOVIO’s team around the clock since January of this year, having maintained a very close collaboration together. INOVIO’s great advantage of rapid DNA plasmid and delivery technologies are very important to the success of this vaccine candidate. After the completion of dosing for Phase 1 trial subjects at Huashan Hospital in Shanghai, China, with regulatory approval, Advaccine quickly launched the Phase 2 clinical trial with Jiangsu Provincial CDC team. With the support of Fengcai ZHU, MD the principle investigator and a well-known vaccine clinical professor and his excellent team members as well as advanced clinical trial infrastructure in Jiangsu Province, I believe we can achieve China Phase 2 enrollment target of 640 subjects by the end of 2020.”

INOVIO and Advaccine have been working together to advance the clinical development of INO-4800 in China. The Phase 2 clinical trial of INO-4800 in China will enroll both 18-59 years old adults and older adults (60 years and older) with the primary endpoints of evaluating safety and immunogenicity within the Chinese population. The dosing regimen involves two vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg dosing levels and is similar to the Phase 2 segment of Phase 2/3 clinical trial in U.S. This trial in China will provide valuable insights on INO-4800 safety and immunogenicity profile to support further evaluation of this vaccine candidate.

INOVIO recently announced it has dosed the first subjects in the Phase 2 segment of its Phase 2/3 clinical trial for INO-4800 in the U.S., called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy). For more information about the clinical trial, see www.clinicaltrials.gov, identifier NCT04642638.

About the INO-4800 “INNOVATE” Phase 2/3 Clinical Trial

The lead Principal Investigator for INNOVATE is Dr. Pablo Tebas, Professor of Medicine at the Hospital of the University of Pennsylvania. The Phase 2 segment of the clinical trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization (in a planned total of 400 subjects) to receive either INO-4800 or placebo, to confirm the more appropriate dosing level for each of three age groups (18-50 years, 51-64 years and 65 years and older) for the subsequent Phase 3 efficacy evaluation. The company strives to ensure diversity in enrollment, targeting specific populations that are working or residing in environments with high risk of exposure to SARS-CoV-2, for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings.

The INNOVATE trial is funded by the U.S. Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA). In the Phase 3 segment of the trial, INOVIO intends to enroll healthy men and non-pregnant women 18 years and older, to evaluate the efficacy of the proposed dosing level(s) for each age group based on the data from the Phase 2 evaluation. Participants will be enrolled in a one-to-one randomization to receive either INO-4800 or a placebo. The Phase 3 segment will be case-driven with the final number of enrollees to be determined by the incidence of COVID-19 during the Phase 3 segment. The primary endpoint of the Phase 3 segment will be virologically confirmed COVID-19 disease.

About INOVIO’s Global Coalition Advancing INO-4800

INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800. To date, the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation, and the U.S. Department of Defense have contributed significant funding to the advancement and manufacturing of INO-4800.R&D collaborators to date include The Wistar Institute, the University of Pennsylvania, the University of Texas, Fudan University and Laval University. INOVIO has partnered with Advaccine and the International Vaccine Institute to conduct clinical trials of INO-4800 in China and South Korea, respectively. INOVIO is also assessing nonclinical efficacy of INO-4800 in several animal challenge models with Public Health England (PHE) and Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia. INOVIO is working with a team of contract manufacturers including Kaneka Eurogentec S.A, Thermo Fisher Scientific, Richter-Helm BioLogics, and Ology Bioservices to manufacture INO-4800 on a commercial scale and is seeking additional external funding and partnerships to further scale up manufacturing capacities to satisfy the urgent global demand for safe and effective vaccines.

About INO-4800

INO-4800 is INOVIO’s DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. INOVIO has extensive experience working with coronaviruses and was the first company to initiate a Phase 2a trial for INO-4700, a DNA vaccine candidate for a related coronavirus that causes Middle East Respiratory Syndrome (MERS).

Composed of an optimized DNA plasmid, INO-4800 is delivered directly into cells in the body via a proprietary smart device to produce a robust, safe and tolerable immune response. INO-4800 is the only nucleic-acid based vaccine that is stable at room temperature for more than a year, at 37^o C for more than a month, has a five-year projected shelf life and does not need to be frozen during transport or storage – which are important considerations when preparing for mass immunizations.

About INOVIO’s DNA Medicines Platform

INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and COVID-19, being developed under grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.

INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO’s proprietary hand-held smart device called CELLECTRA^®. The CELLECTRA^® device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA^® device ensures that the DNA medicine is efficiently delivered directly into the body’s cells, where it can go to work to drive an immune response. INOVIO’s DNA medicines do not interfere with or change in any way an individual’s own DNA. The advantages of INOVIO’s DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials.

With more than 2,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.

About Advaccine

Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”) is an emerging clinical stage immunotherapy company pioneering novel preventive and therapeutic vaccines against infectious diseases, cancers and autoimmune diseases. Advaccine exploits a wide range of vaccine applications, with innovative antigen technologies, its adjuvant platform and along with a cellular immunity assessment platform for the swift development of novel vaccine and immunotherapeutic candidates. Through years of innovative preclinical and clinical research, Advaccine has successfully built a broad portfolio of vaccine candidates including a preventive vaccine based on a novel adjuvant targeting respiratory syncytial virus (RSV) infection in the elderly and infants, an immunotherapeutic vaccine against chronic hepatitis B (CHB), and also immunotherapeutic vaccine candidates against autoimmune diseases and various cancers. Based on its deep expertise in vaccine research and in-house large-scale manufacturing capabilities, Advaccine has been able to bring several vaccine candidates to clinical stages and ready for late stage clinical testing and commercial launch in the near future.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO’s lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DOD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, [email protected] 
Investors: Ben Matone, 484-362-0076, [email protected]

This press release contains certain forward-looking statements relating to our business, including our plans to develop and manufacture DNA medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of the Phase 2/3 clinical trial of INO-4800, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in preclinical studies, clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

 

View original content:http://www.prnewswire.com/news-releases/inovio-and-advaccine-announce-first-dosing-of-subject-in-phase-2-clinical-trial-for-covid-19-dna-vaccine-candidate-ino-4800-in-china-301190178.html

SOURCE INOVIO Pharmaceuticals, Inc.

SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces results from a prospective study showing Target Selector™ was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer.  The results were featured yesterday in a poster presentation by Vered Stearns, M.D., professor of oncology, breast cancer research chair in oncology, and director of the Women’s Malignancies Disease Group at Johns Hopkins University School of Medicine/Johns Hopkins Sidney Kimmel Cancer Center, at the virtual 2020 San Antonio Breast Cancer Symposium® (SABC®).  The poster can be found under the “breast cancer” tab here. 

“Approximately 20% of newly diagnosed breast cancer is HER2 positive, but during treatment and as the disease progresses, HER2 receptor conversion may occur,” said Dr. Stearns.  “Once breast cancer metastasizes, it may be difficult to access multiple sites or perform serial tissue biopsies to monitor for conversion.  In this study, liquid biopsy testing proved to be a highly sensitive and specific mechanism for monitoring HER2 receptor changes over time.”

“Target Selector™ has been shown to be a highly sensitive blood-based testing method for identifying changes in HER2 status, and is less invasive, more time efficient and more cost effective compared to tissue biopsy,” said Michael Nall, President and CEO.  “Target Selector™ provides critical information to identify patients who may benefit from the addition of anti-HER2 therapy and those on anti-HER2 therapy for whom additional therapeutic options may warrant consideration.”

About SABCS®
Since 1977 the San Antonio Breast Cancer Symposium® (SABCS®) has been the leading scientific conference for basic scientists, physician-scientists, clinical investigators and breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis and therapy of premalignant breast disease and breast cancer.  Founded, owned and operated by UT Health San Antonio, the symposium has grown to a five-day event attended by an international audience of academic investigators and private physicians from over 80 countries to attain information through abstract presentations, panel discussions, research findings and state-of-the-art educational sessions.  UT Health San Antonio, the American Association for Cancer Research (AACR) and Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine support SABCS, which provides education and accessibility to the latest information regarding the prevention, diagnosis and treatment of premalignant breast cancer and breast disease.  For more information about the symposium, please visit www.sabcs.org.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.  The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA).  With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options.  Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic.  For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding Target Selector being less invasive, more time efficient and more cost effective compared to tissue biopsy, Target Selector providing critical information to identify patients who may benefit from the addition of anti-HER2 therapy and those on anti-HER2 therapy for whom additional therapeutic options may warrant consideration, the ability of our tests to provide clinically actionable information and the ability of Biocept’s platform to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including the risk that our products and services may not perform as expected. These and other risks are described in greater detail under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

Investor Contact

:
 

LHA Investor Relations

Jody Cain

[email protected] 
310-691-7100

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-liquid-biopsy-demonstrated-high-accuracy-when-used-for-monitoring-the-progression-of-metastatic-breast-cancer-in-study-conducted-at-johns-hopkins-sidney-kimmel-cancer-center-301190300.html

SOURCE Biocept, Inc.

HOUSTON, Dec. 10, 2020 /PRNewswire/ — LyondellBasell (NYSE: LYB) one of the world’s largest plastics, chemicals and refining companies today announced it has joined the United Nations (U.N.) Global Compact, the world’s largest corporate sustainability initiative. Under the U.N. Global Compact, signatories are encouraged to align their operations and strategies with key principles on human rights, labor and anti-corruption.

“At LyondellBasell, we have a culture of accomplishing goals through what we call ‘the power of many.’ Addressing the challenges facing our world will require global commitment and collaboration between the private sector, NGOs and governments,” said Bob Patel, CEO Of LyondellBasell. “The goals of the U.N. Global Compact align well with our company’s focus on eliminating plastic waste in the environment, addressing climate change and supporting a thriving society. We are proud to be part of this important, collective effort.” 

In 2020, LyondellBasell advanced its sustainability agenda by setting ambitious targets for recycled and renewable-based polymers, progressing on the goal of zero polymer pellet loss from operations and transportation and starting up the MoReTec molecular recycling pilot plant in Ferrara, Italy. In addition, the company is one of the founding members of the Alliance to End Plastic Waste (AEPW), the first global, cross value chain initiative dedicated to eliminating plastic waste in the environment.

For more information about LyondellBasell’s sustainability efforts, visit the company’s sustainability page. For more information on the company’s involvement as a participant of the initiative, visit the company’s profile page on the UN Global Compact website.

About LyondellBasell

LyondellBasell (NYSE: LYB) is one of the largest plastics, chemicals and refining companies in the world. Driven by its employees around the globe, LyondellBasell produces materials and products that are key to advancing solutions to modern challenges like enhancing food safety through lightweight and flexible packaging, protecting the purity of water supplies through stronger and more versatile pipes, improving the safety, comfort and fuel efficiency of many of the cars and trucks on the road, and ensuring the safe and effective functionality in electronics and appliances. LyondellBasell sells products into more than 100 countries and is the world’s largest producer of polymer compounds and the largest licensor of polyolefin technologies. LyondellBasell offers a circular product portfolio that provides customers with solutions to increase recycled plastic content in their applications with high quality mechanically recycled polymers. In 2020, LyondellBasell was named for the third consecutive year to Fortune magazine’s list of the “World’s Most Admired Companies.” More information about LyondellBasell can be found at www.LyondellBasell.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lyondellbasell-joins-the-united-nations-global-compact-301190159.html

SOURCE LyondellBasell Industries

SEATTLE, Dec. 10, 2020 /PRNewswire/ — With Alaska Airlines’ membership in oneworld less than four months away, both companies announced today that Alaska’s elite Mileage Plan members will receive matching oneworld tier status in the global alliance:

• MVP Gold 75K = oneworld Emerald
• MVP Gold = oneworld Sapphire
• MVP = oneworld Ruby

Many of the benefits elite flyers currently enjoy on Alaska with their status will seamlessly carry over to the oneworld tiers when they travel on any of the 13 global oneworld member airlines. This means they’ll be able to take advantage of a variety of privileges, including priority check-in, access to international first and business class lounges, preferred boarding, fast track through security, baggage benefits and more.

Alaska joins oneworld on March 31, 2021. Matching oneworld tier status happens automatically at that time.

“Our upcoming membership in oneworld opens up endless possibilities, especially for our elite Mileage Plan members,” said Ben Minicucci, Alaska’s president. “As the airline industry continues to recover, we expect an increasing number of our guests to look ahead to international travel once again. If you’ve worked hard to earn status with us, all that hard work will go even further with benefits in oneworld to make your journey even more enjoyable.”

For example, beginning March 31, an Alaska MVP Gold member will receive oneworld Sapphire status right away. If that traveler then takes a trip from San Francisco to Doha on Qatar Airways, they’ll have access to business class lounges, business class priority check-in and priority boarding, regardless of the class of service they’re flying in.

“We are excited to announce the oneworld benefits that Alaska Airlines Mileage Plan customers can expect when Alaska joins the alliance next year – unlocking more benefits and destinations for the airline’s frequent flyers,” said oneworld CEO Rob Gurney. “With its strong network on the U.S. West Coast and award-winning customer service, Alaska’s membership will position oneworld to offer even more privileges and options to our member airlines and customers.”

Alaska will be the 14^th full member of oneworld. The current 13 full members of the alliance are: American Airlines; British Airways; Cathay Pacific; Finnair; Iberia; Japan Airlines; Malaysia Airlines; Qantas; Qatar Airways; Royal Air Maroc; Royal Jordanian; S7 Airlines and SriLankan Airlines. Fiji Airways is a oneworld connect partner. Prior to COVID-19, the alliance’s global network offered flights to more than 1,000 destinations in more than 170 countries and territories.

Alaska Airlines and its regional partners serve more than 115 destinations across the United States and North America. The airline provides essential air service for our guests along with moving crucial cargo shipments, while emphasizing Next-Level Care. Alaska is known for low fares, award-winning customer service and sustainability efforts. Guests can earn and redeem miles on flights to more than 800 destinations worldwide with Alaska and its Global Partners. On March 31, 2021, Alaska will officially become a member of the oneworld global alliance. Learn more about Alaska at newsroom.alaskaair.com and blog.alaskaair.com. Alaska Airlines and Horizon Air are subsidiaries of Alaska Air Group (NYSE: ALK).

View original content to download multimedia:http://www.prnewswire.com/news-releases/alaska-airlines-and-oneworld-announce-benefits-for-elite-mileage-plan-members-301190282.html

SOURCE Alaska Airlines

CALGARY, AB and NEW YORK, Dec. 10, 2020 /PRNewswire/ – Railway Age Magazine has named Canadian Pacific President and CEO Keith Creel the 58th annual recipient of its Railroader of the Year Award. A cover profile of Mr. Creel and his leadership at CP will appear in the January 2021 issue.

“Keith Creel has been instrumental in Canadian Pacific forging a leadership role in the industry while acknowledging the railroad’s place in history and its role in driving the North American economy forward,” said Railway Age Editor-in-Chief William C. Vantuono. “He has helped renew Canadians’ and CP employees’ sense of pride in a company that connected a nation, and connected Canada to the rest of the world. Under his steady hand, and under very difficult circumstances this past year, CP is a safe, efficient and productive railroad, enabling its customers to connect with domestic and global markets.”

Mr. Creel became President and CEO of Canadian Pacific on Jan. 31, 2017, and is the 17th person to lead the company since its founding in 1881. He was appointed President and Chief Operating Officer in February 2013 and joined the CP Board of Directors in May 2015.

“I am proud to accept this honor on behalf of the entire CP family of railroaders,” Creel said. “It is one of the great privileges of my lifetime to lead the dedicated people who make this iconic company run safely and efficiently. 2020 has been extraordinary in so many ways and our individual and collective commitment to excellence has never been stronger.”

Prior to joining CP, Mr. Creel was Executive Vice-President and Chief Operating Officer at CN. He held various positions at CN, including Executive Vice-President Operations, Senior Vice-President Eastern Region, Senior Vice-President Western Region and Vice-President of the Prairie Division. Mr. Creel began his railroad career at Burlington Northern Railway in 1992 as an Intermodal Ramp Manager in Birmingham, Ala. He also spent part of his career at Grand Trunk Western Railroad as a Superintendent and General Manager, and at Illinois Central Railroad as a Trainmaster and Director of Corridor Operations, prior to its merger with CN in 1999. Mr. Creel holds a Bachelor of Science in Marketing from Jacksonville State University and also completed the Advanced Management Program at the Harvard Business School. He has a military background as a commissioned officer in the U.S. Army, during which time he served in the Persian Gulf War in Saudi Arabia.

Mr. Creel is the third Canadian Pacific leader to win the award.

Railway Age’s

Railroader of the Year Award

The Railroader of the Year Award was initiated by Modern Railroads magazine in 1964 as the “Man of the Year” award. Railway Age acquired Modern Railroads in 1991 and has presented the award annually since then. For a full list of Railroader of the Year winners, click here.

About Canadian Pacific

Canadian Pacific is a transcontinental railway in Canada and the United States with direct links to major ports on the west and east coasts. CP provides North American customers a competitive rail service with access to key markets in every corner of the globe. CP is growing with its customers, offering a suite of freight transportation services, logistics solutions and supply chain expertise. Visit cpr.ca to see the rail advantages of CP. CP-IR

About Railway Age

In business since its establishment in Chicago in 1856, Railway Age is the transportation industry’s longest-running trade publication, covering railway technology, operations, strategic planning, marketing, equipment finance and other topics such as legislative, regulatory and labor/management developments. What began as a weekly in the mid-19th century is, in the 21st century, an information resource incorporating digital and print publishing of a monthly magazine, a website (www.railwayage.com); daily and weekly electronic newsletters (Rail Group News, Innovations); webinars; social media (Twitter, Facebook and LinkedIn); Rail Group On Air Podcasts; industry conferences; and custom publishing services.

View original content:http://www.prnewswire.com/news-releases/railway-age-names-canadian-pacifics-keith-creel-railroader-of-the-year-2021-301189909.html

SOURCE Canadian Pacific

SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Nuvve Corporation, a San Diego-based, green energy technology company and a leader in vehicle-to-grid (V2G) technology, has begun using the batteries on five electric school buses (e-buses) to provide power to Con Edison’s grid, marking the first time in New York State history that electricity has flowed from buses into a utility’s grid.

The e-buses are from Lion Electric, a North American leader in heavy-duty zero emission transportation with which Nuvve recently announced a collaboration to provide V2G-enabled school buses. By day, these e-buses carry students to schools in the White Plains area, displacing their diesel-powered counterparts. E-buses have shown to provide a cleaner ride for kids and, with lower CO2 emissions, can help better the air quality in the Westchester County community.

The project began in 2018 as a partnership among Lion, Nuvve, White Plains School District, National Express and First Priority Group with 5 electric school buses. The charging and discharging takes place at a depot in North White Plains. When plugged in, Nuvve’s V2G platform determines the optimal time to charge according to when rates are lowest. On nights and weekends, when the buses are parked and not in use, the system reverses the flow of power – 10 kilowatts from each bus – into the grid.

The goal of the project is to explore the technological and economic potential of using e-buses on a wider scale to improve air quality and grid reliability. There are approximately 1,000 school buses operating in Westchester and 8,000 in New York City that could make a significant difference to the environment if converted to electric with V2G capability.

“We think electric school buses may provide an opportunity to achieve two of our company’s goals: reducing carbon emissions and maintaining our industry-leading reliability” said Brian Ross, Con Edison’s manager for the project. “We are innovating to help our state and region achieve a clean energy future in which electric vehicles will have a big role.”

The White Plains school district put the buses on the road for the 2018-2019 school year and has found them to be a reliable source of transportation to date. Nuvve’s V2G software platform ensures that the energy delivered to the buses is prioritized to perform their daily driving routes while still delivering grid services when needed.

The upfront cost of e-buses is higher than traditional diesel ones. However, V2G enables the e-buses to discharge energy back to the grid and perform grid services, both of which can result in shared revenue and can help lower the total cost of ownership. These savings help make e-buses more attractive to school districts, the communities they serve, and the bus operators that provide the service.

“Our V2G software platform is designed to deliver grid services such as those to Con Edison from electric school buses”, said Gregory Poilasne, chairman and CEO of Nuvve Corporation. “The electric buses provide a cleaner environment for communities and help lower CO2 emissions while ensuring that driving energy needs are met every day.”

School schedules match up well with the power needs of Con Edison’s 3.5 million customers. School buses are generally idle during the summer, which is when utility customers’ need for power rises due to an increased use of air conditioning. Discharging power from a sufficient number of electric buses into the grid at these times of high demand would take stress off Con Edison electric-distribution equipment and increase grid resilience.

Nuvve is building alliances with both utilities and school bus manufacturers to enable a national roll out of V2G-enabled school buses, which Nuvve believes will eventually replace diesel buses at a competitive cost. Nuvve’s proprietary energy aggregator platform, called GIVe™, has been used around the world to transform electric vehicles into distributed energy resources (DERs) that can be controlled to deliver specific energy services to the grid.

Nuvve announced recently a definitive merger agreement with Newborn Acquisition Corp. (Nasdaq: NBAC), which will result in Nuvve becoming a listed public company at closing.

About Nuvve Corporation
Nuvve Corporation is a San Diego-based green energy technology company whose mission is to lower the cost of electric vehicle ownership while supporting the integration of renewable energy sources, including solar and wind. Our proprietary vehicle-to-grid (V2G) technology – Nuvve’s Grid Integrated Vehicle (GIVe™) platform – is refueling the next generation of electric vehicle fleets through cutting-edge, bidirectional charging solutions. Since its founding in 2010, Nuvve has been responsible for successful V2G projects on five continents and is deploying commercial services worldwide. For more information please visit www.nuvve.com or follow us on LinkedIn and Twitter.

Nuvve Press Contact
Marc Trahand, EVP Marketing
[email protected]
+1 858 250 9740

Nuvve Investor Contact
Lytham Partners
Robert Blum
[email protected]
+1 602 889 9700

About Newborn Acquisition Corp.

Newborn Acquisition Corp. is a blank check company, holding approximately $57.5 million in its trust account, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Important Information and Where to Find it

In connection with the proposed business combination, Nuvve Holdings, as the successor to Newborn, will file a registration statement on Form S-4 (the “Form S-4”) with the SEC. The Form S-4 will include a preliminary proxy statement/prospectus of Newborn and Nuvve Holdings, which Newborn will file with the SEC as a proxy statement on Schedule 14A, for the solicitation of proxies from Newborn’s shareholders and for the offering of Nuvve Holdings’ securities to the security holders of Newborn and Nuvve in the business combination. Additionally, Newborn and Nuvve Holdings will file other relevant materials with the SEC in connection with the business combination. Copies may be obtained free of charge at the SEC’s web site at www.sec.gov. The definitive proxy statement/prospectus will be mailed to Newborn shareholders as of a record date to be established for voting on the proposed business combination. Investors and security holders of Newborn are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information about the business combination and the parties to the business combination. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

Newborn and its directors and officers may be deemed participants in the solicitation of proxies of Newborn’s shareholders in connection with the proposed business combination. Nuvve and its officers and directors may also be deemed participants in such solicitation. Security holders may obtain more detailed information regarding the names, affiliations and interests of certain of Newborn’s executive officers and directors in the solicitation by reading Newborn’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and the proxy statement/prospectus and other relevant materials filed with the SEC in connection with the business combination when they become available. Information concerning the interests of Newborn’s participants in the solicitation, which may, in some cases, be different than those of their stockholders generally, will be set forth in the proxy statement/prospectus relating to the business combination when it becomes available.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

Forward Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this presentation, regarding the proposed business combination between Newborn and Nuvve and Nuvve’s strategy, future operations, estimated and projected financial performance, prospects, plans and objectives are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Newborn and Nuvve disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Newborn and Nuvve caution you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of either Newborn or Nuvve. In addition, Newborn cautions you that the forward-looking statements contained in this press release are subject to the following factors: (i) the occurrence of any event, change or other circumstances that could delay the business combination or give rise to the termination of the agreements related thereto; (ii) the outcome of any legal proceedings that may be instituted against Newborn or Nuvve following announcement of the transactions; (iii) the inability to complete the business combination due to the failure to obtain approval of the shareholders of Newborn, or other conditions to closing in the merger agreement; (iv) the risk that the proposed business combination disrupts Nuvve’s current plans and operations as a result of the announcement of the transactions; (v) Nuvve’s ability to realize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of Nuvve to grow and manage growth profitably following the business combination; (vi) costs related to the business combination; (vii) risks related to the rollout of Nuvve’s business and the timing of expected business milestones; (viii) Nuvve’s dependence on widespread acceptance and adoption of electric vehicles and increased installation of charging stations; (ix) Nuvve’s ability to maintain effective internal controls over financial reporting, including the remediation of identified material weaknesses in internal control over financial reporting relating to segregation of duties with respect to, and access controls to, its financial record keeping system, and Nuvve’s accounting staffing levels; (x) Nuvve’s current dependence on sales of charging stations for most of its revenues; (xi) overall demand for electric vehicle charging and the potential for reduced demand if governmental rebates, tax credits and other financial incentives are reduced, modified or eliminated or governmental mandates to increase the use of electric vehicles or decrease the use of vehicles powered by fossil fuels, either directly or indirectly through mandated limits on carbon emissions, are reduced, modified or eliminated; (xii) potential adverse effects on Nuvve’s revenue and gross margins if customers increasingly claim clean energy credits and, as a result, they are no longer available to be claimed by Nuvve; (xiii) the effects of competition on Nuvve’s future business; (xiv) risks related to Nuvve’s dependence on its intellectual property and the risk that Nuvve’s technology could have undetected defects or errors; (xv) changes in applicable laws or regulations; (xvi) the COVID-19 pandemic and its effect directly on Nuvve and the economy generally; (xvii) risks related to disruption of management time from ongoing business operations due to the proposed business combination; (xvii) risks relating to privacy and data protection laws, privacy or data breaches, or the loss of data; and (xix) the possibility that Nuvve may be adversely affected by other economic, business, and/or competitive factors. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Newborn has filed and will file from time to time with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Newborn’s SEC filings are available publicly on the SEC’s website at www.sec.gov.

View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvve-corporation-activates-bidirectional-flow-of-energy-from-electric-school-buses-to-con-edisons-grid-in-new-york-301190054.html

SOURCE Nuvve Corporation